MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Characterisation of OFF-Time in Levodopa-Treated Parkinson’s Patients: A Post-hoc Analysis of an Exploratory Trial

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, B. Guimarães, J-F. Rocha (Lisbon, Portugal)

    Objective: This analysis aims to study the evolution of OFF and ON patterns during a 12-hour daily period in patients with Parkinson’s disease (PD) and…
  • 2023 International Congress

    Differential Rab10 & Rab8A phosphorylation by LRRK2 variants G2019S & I1371V manifests differences in membrane fluidity & pathogenicity.

    KH. Singh, IND. Datta (Bengaluru, India)

    Objective: To evaluate the difference in substrate (Rab8A & Rab10) phosphorylation by LRRK2 variants G2019S & I1371V on membrane fluidity & pathogenicity. Background: LRRK2 is…
  • 2023 International Congress

    PSP-like phenotype triggered by STN DBS in PD: a case report

    W-H. Chang, Y-C. Chen, P-L. Chen, P-H. Tu, C-H. Yeh, T-C. Liu, C-S. Lu, C-C. Chen (Taoyuan, Taiwan)

    Objective: We report on a patient with Parkinson’s disease (PD) who developed reversible Progressive Supranuclear Palsy (PSP) like phenotype after bilateral subthalamic nuclear (STN) deep…
  • 2023 International Congress

    Elevated plasma CREG1 levels are linked to a lower risk of Parkinson’s disease

    X. Guo, R. Zhou, G. Tian, R. Li (Xi'an, China)

    Objective: The purpose of this study is to assess the causal associations between plasma cellular repressor of E1A-stimulated genes 1 (CREG1) levels and the risk…
  • 2023 International Congress

    Role of bilateral pallidotomy in status dystonicus

    K. Garg, M. Singh, R. Rajan (New Delhi, India)

    Objective: The purpose of this study is to retrospectively review the results of bilateral pallidotomy in patients presenting with status dystonicus. Background: Dystonias, third commonest…
  • 2023 International Congress

    Frequency of Parkinson disease following COVID-19 infection: a two-year retrospective cohort study

    A. Wang, J. Perez, S. Gunzler (Cleveland, USA)

    Objective: We aimed to utilize a large healthcare research network to determine the risk of developing Parkinson disease following COVID-19 infection compared individuals without COVID-19…
  • 2023 International Congress

    Home-based titration with Duodenal infusion of Levodopa in People with Parkinson’s disease: an observational feasibility study

    B. Biering-Sørensen, N. Nielsen, A. Isenberg, L. Olsen, M. Javidi, J. Vilhelmsen, M. Møller, M. Olsen, J. Clausen, T. Thomsen (Glostrup, Denmark)

    Objective: Primary objectives were to assess the feasibility and safety of LCIG home titration with use of telemedicine-assisted (TM) technology, and  patient/caregivers satisfaction. Secondly, to…
  • 2023 International Congress

    Network localization of limb ataxia

    J. Pullinen, O. Liesmäki, O. Likitalo, A. Bellmunt Gil, J. Aaltonen, E. Mäkinen, E. Ellis, P. Ylikotila, J. Joutsa (Turku, Finland)

    Objective: To identify the neural substrates of limb ataxia caused by stroke lesions. Background: Ataxia is a neurological sign defined by incoordination of voluntary movements.…
  • 2023 International Congress

    Mesencephalic neuroglial cyst can produce clinical manifestations and a metabolic [18F] FDG PET pattern mimicking a Progressive Supranuclear Palsy Syndrome

    C. Espinoza-Vinces, V. Betech-Antar, A. Atorrasagasti, S. Solís-Barquero, C. Arrondo, G. Montoya, G. Martí-Andrés, MR. García-Eulate, J. Arbizu, MR. Luquin (Pamplona, Spain)

    Objective: To describe the clinical manifestations and structural and functional neuroimaging findings in a patient with a left mesencephalic neuroglial cyst, resembling a PSP. Background:…
  • 2023 International Congress

    Motor function in Parkinson´s disease during 16h treatment with intravenously (DIZ101), subcutaneously (DIZ102), or intestinally (LCIG) infused levodopa

    F. Bergquist, M. Ehrnebo, D. Nyholm, A. Johansson, F. Lundin, P. Odin, P. Svenningsson, N. Dizdar, E. Eriksson (Gothenburg, Sweden)

    Objective: To compare the effect of intravenous (DIZ101) and subcutaneous (DIZ102) continuous 16h infusion of a continuously buffered acidic levodopa/carbidopa solution with levodopa/carbidopa intestinal gel…
  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley